Disorders of the nervous system is very rare (<1/10000). Cases of cerebrovascular disorders including cerebral infarction and cerebral ischemia: see below under “Serious side effects in clinical practice.”
Skin reactions and disorders of the subcutaneous tissue
is possible appearance of skin rash
Vascular disorders Very rare (<1/10000) Cases of venous thrombosis: see below under “Serious side effects in clinical practice,” There are cases of bleeding during treatment with NovoSeven drug.. It is assumed that NovoSeven is not the cause of the bleeding, but the bleeding had already arisen may continue in case of trenbolone enanthate stack insufficient efficacy or wrong dosage of the drug.
In the post-marketing phase of the following serious side effects have been reported:
- Arterial thrombosis, myocardial infarction or ischemia, cerebrovascular pathology and bowel infarction. The vast majority of patients with these complications had a predisposition to the development of arterial thrombosis (comorbidities, age, atherosclerosis, or other violations described in the section “Special warnings and special precautions”).
- Venous thrombosis: thrombosis, deep vein thrombosis and complications – pulmonary embolism. The vast majority of these patients have a predisposition to the development of venous thrombosis due to the presence of associated risk factors. Patients who are at risk of developing venous thrombosis due to underlying medical conditions, the presence of a history of thrombosis, immobilization in the postoperative period or vein catheterization, need careful monitoring.
Spontaneous anaphylactic reactions in clinical practice has not been registered, however, patients with allergic history require careful monitoring. Antibodies to factor VII in patients with hemophilia A and B have been identified. Describes certain cases the appearance of antibodies to factor VII NovoSeven after application of the drug in patients with deficiency of factor VII. These patients previously poured human plasma and / or plasmatic factor VII. Two patients have been identified in vitro inhibitory effect of antibodies. Patients with Factor VII deficiency control should be performed on the antibody to Factor VII. It described one case of angioneurotic edema in a patient suffering Glantsmana thrombasthenia after administration of NovoSeven drug.
In elderly patients (older than 80 years) male suffering from deficiency of factor VII, at a dose of drug received exceeds the recommended dose 10-20 times observed thrombotic complication other thrombotic complications from overdoses were observed, including, after the treatment of 6-year-old boy suffering from hemophilia a with inhibitors who received the drug in doses exceeding the recommended dose is 8-10 times.
Interaction with other drugs
Data on the risk of potential drug interactions between NovoSeven and coagulation factor concentrates are missing. It should not be administered simultaneously prothrombin complex concentrates (activated or not activated) and NovoSeven According to reports, Antifibrinolytics reduce intraoperative blood loss in trenbolone enanthate stack patients with hemophilia, especially in orthopedic surgery and operations on the high fibrinolytic activity of tissues, such as in the oral cavity. Experience combined use antifibrinolytics and drug NovoSeven limited.
Monitoring during treatment – laboratory studies
of drug therapy NovoSeven does not require laboratory monitoring. Doses are determined depending on the severity of the bleeding and clinical effect. It was shown that after administration of NovoSeven, prothrombin time (PT) and activated partial thromboplastin time (aPTT) is reduced, however, the correlation between the PT and aPTT and clinical efficacy of NovoSeven drug has been identified.
In pathological conditions associated with an increased release of tissue factor, use of the drug NovoSeven can be associated with a potential risk of thrombotic complications or disseminated intravascular coagulation (DIC) These conditions include severe atherosclerosis, crush injury, septicemia and DIC. As recombinant coagulation factor VIIa – drug NovoSeven – may contain trace amounts of mouse IgG, bovine IgG and other residual culture proteins (whey proteins hamsters and cows), in patients receiving the drug, there is very little opportunity to develop hypersensitivity to these proteins. In severe bleeding drug is desirable to use in clinics specializing in the treatment of hemophilia with inhibitors to coagulation factors VIII or the IX, and if this is not possible, in close collaboration with a physician specialized in haemophilia treatment duration of outpatient therapy should not exceed 24 hours. If during this time you can not stop the bleeding, the patient required hospitalization. Patients or carers for them, should, at the earliest opportunity, notify your doctor or clinic about every case of NovoSeven preparation in the home. Patients with a deficiency of factor VII, prothrombin time must be monitored and Factor VII activity before and after administration of the drug NovoSeven. If the activity of factor VIIa does not reach the expected level or bleeding continues, despite the use of the drug at the recommended doses of antibodies can be assumed. In this case, it should be analyzed for the presence of antibodies. Data on the risk of thrombosis in patients with factor VII deficiency on the background of treatment with NovoSeven are not available. Unused products and waste should be disposed of in accordance with local requirements.
Use during pregnancy and lactation
As shown by animal studies, intravenous drug NovoSeven no influence on fetal growth, fertility and reproductive properties. It is not known whether NovoSeven is able when administered to a pregnant woman to cause fetal damage or lead to a breach of reproductive function. The use of NovoSeven drug in pregnant women should be limited to the strict indications. Use during lactation: It is not known whether NovoSeven is excreted in breast milk. Caution should be exercised when administering the drug NovoSeven to nursing mothers.
Valium for drug of a solution for intravenous administration of 1.2 mg (60 CUD); 2.4 mg (120 CUD) or 4.8 mg (240 CUD) in the vial of colorless glass, corked lyophilization of bromobutyl rubber, aluminum cap and plastic cover «Snap-off», together with the solvent (water for injection) vial of colorless glass, corked from bromobutyl rubber coated with Teflon inside, aluminum cap and plastic cover «Snap-off», a sterile vial adapter (for breeding); sterile disposable polypropylene syringe for dilution and administration; sterile system for transfusion; two alcohol swabs for processing rubber stoppers on the vials;instructions for use in a box made of cardboard.
Shelf life of the drug in the commercial package is 3 years.
It has been shown that at 25 ° C the drug retains chemical and physical properties within 24 hours of reconstitution. From a microbiological point of view, the preparation should be used immediately after dilution. In that case, if the entire diluted formulation is introduced not directly responsible for trenbolone enanthate stack the duration and storage conditions (typically, it is not more than 24 hours at a temperature of from 2 ° C to 8 ° C), the user carries, except dilution of the drug in a controlled, aseptically confirmed in due course. Do not use after the expiration date. steroid purchase online steroid suppliers uk buy steroids online mexican hgh eurolab steroids buy steroids from mexico